Celerion Celebrates 80 Years of Conducting Business at Global Headquarters in Lincoln, Nebraska
(Lincoln, NE; Dec 17, 2013) – Celerion is proud to announce the 80th anniversary of operations at our first facility in Lincoln, Nebraska. Celerion is at the forefront of early clinical research with corporate headquarters in Lincoln, plus seven other facilities globally involving 950 employees and over 750 beds of capacity. Celerion has proudly supported the development of many experimental and currently marketed drugs by conducting over 6000 clinical studies globally, including support for agents that treat diabetes, hypertension, blood lipid disorders, obesity, gastrointestinal conditions, respiratory diseases, inflammation, pain neurologic disease, infections, and reproductive health.
The operations in Lincoln started in 1933, with legacy company Harris Laboratories, and were focused on the science of food testing, analysis of water and animal feeds and later, agricultural testing. In 1969 the focus of the company expanded to healthcare by offering comprehensive clinical research services. At that time the company was one of the first to offer an independent clinical research testing environment and in doing so, helped to create the contract clinical research industry. Celerion was formed in 2010 through the acquisition of the early stage development operations of MDS Pharma Services. Prior to that, the facility in Lincoln conducted business under the name MDS Harris, following the acquisition by MDS Inc. an international healthcare organization.
Celerion’s facility in Lincoln is one of the few sites in the industry offering clinical study conduct, clinical pharmacology data analysis and reporting, plus a large supporting bioanalytical laboratory in one location. The facility also has an on-site ADME suite capable of handling radiotracers, a USP <797> Clean Room, microdosing capabilities and has conducted over 300 First-In-Human studies. Our alliance with Bryan Health Hospital which includes 24 on-site beds, has enabled access to conduct complex studies by leveraging their personnel and state-of-the-art techniques and equipment, including MRI, PET scans, CT, EMG, EGD and CNS/cognitive testing.
“We are extremely proud of our 80 year heritage and the impact of our services globally,” said Susan Thornton PhD, President and CEO of Celerion. “Harris Laboratories was visionary in developing innovative clinical research services for the pharmaceutical industry. Celerion continues this legacy in Applied Translational Medicine by leveraging our experience, expertise, innovative technologies and access to patients earlier in clinical research.”
Celerion continues to focus on ways to deliver high-quality clinical pharmacology that enables better decision making for new products in development for our clients, and makes a positive impact on disease management and the public health.
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, cardiac safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. For more information please visit www.celerion.com.
Executive Director, Global Marketing